⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INKT News
MiNK Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
INKT
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
globenewswire.com
INKT
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
globenewswire.com
INKT
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
globenewswire.com
INKT
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
globenewswire.com
INKT
Form 8-K
sec.gov
INKT
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
globenewswire.com
INKT
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
prnewswire.com
GTBP
IPHA
INKT
IPSC
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
globenewswire.com
INKT
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
globenewswire.com
INKT